Bianca Weinstock-Guttman

Bianca Weinstock-Guttman's AcademicInfluence.com Rankings

Medical

#2318

World Rank

#2735

Historical Rank

Neurology

#220

World Rank

#296

Historical Rank

medical Degrees

Bianca Weinstock-Guttman

Philosophy

#6768

World Rank

#9863

Historical Rank

Logic

#3884

World Rank

#5109

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Bianca Weinstock-Guttman's Degrees

Doctorate Medicine University of Bucharest

Why Is Bianca Weinstock-Guttman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bianca Weinstock-Guttman is an American neurologist. She is a SUNY Distinguished Professor at the University at Buffalo. Early life and education Weinstock-Guttman completed her medical degree at the University of Bucharest in 1983 and her internship at Meir Hospital and Tel Aviv University.

(See a Problem?)

Bianca Weinstock-Guttman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis (1996) (2476)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. (2006) (1274)
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) (2006) (679)
Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change (2005) (537)
Thalamic atrophy and cognition in multiple sclerosis (2007) (470)
Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. (2004) (382)
Eight-year follow-up study of brain atrophy in patients with MS (2002) (370)
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis (1998) (326)
Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis (1998) (320)
Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test (2007) (308)
Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. (2006) (301)
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study (2007) (299)
Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis (2003) (291)
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis (2011) (284)
Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis (2006) (281)
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis (2004) (263)
The incidence and significance of anti-natalizumab antibodies (2007) (260)
Reliable screening for neuropsychological impairment in multiple sclerosis (2004) (241)
The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis (1995) (228)
Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test (2010) (228)
Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline (2010) (217)
Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS (2009) (217)
Health‐related quality of life in multiple sclerosis: effects of natalizumab (2007) (190)
Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis A case-control study (2012) (187)
Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire (2008) (182)
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis (2018) (179)
Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy (2008) (179)
The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction (2005) (178)
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis (2011) (178)
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). (2006) (174)
Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients (2005) (174)
Diversity and plasticity of self recognition during the development of multiple sclerosis. (1997) (174)
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis (2008) (169)
The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) (2009) (161)
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis (2005) (161)
Unemployment in multiple sclerosis: the contribution of personality and disease (2012) (158)
Management of multiple sclerosis. (1997) (155)
Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis (2006) (153)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (139)
Common viruses associated with lower pediatric multiple sclerosis risk (2011) (138)
Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. (2009) (136)
Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis (2009) (132)
Epidemiology and treatment of multiple sclerosis in elderly populations (2019) (130)
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. (2000) (130)
The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. (2009) (128)
Upper and Lower Extremity Motor Function and Cognitive Impairment in Multiple Sclerosis (2011) (128)
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS (2001) (128)
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis (2007) (127)
Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis (2013) (124)
Gut microbiota composition and relapse risk in pediatric MS: A pilot study (2016) (123)
Risk of bone loss in men with multiple sclerosis (2004) (122)
A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations (2000) (121)
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine (2016) (120)
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients (1995) (118)
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis (2011) (118)
Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS (2017) (118)
Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis (2007) (117)
Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis (2015) (116)
Extended interval dosing of natalizumab in multiple sclerosis (2016) (114)
Younger children with MS have a distinct CSF inflammatory profile at disease onset (2010) (114)
Aging and multiple sclerosis (2016) (114)
MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis (2005) (114)
Multiple sclerosis characteristics in A frican A merican patients in the New York State Multiple Sclerosis C onsortium (2003) (113)
Clinical features of children and adolescents with multiple sclerosis (2007) (112)
Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 (2003) (112)
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing–remitting multiple sclerosis patients compared with normal subjects (2001) (111)
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. (2005) (109)
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis (2014) (108)
Regional lobar atrophy predicts memory impairment in multiple sclerosis. (2005) (108)
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event (2013) (108)
Treatment of pediatric multiple sclerosis and variants (2007) (108)
Rapid disease course in African Americans with multiple sclerosis (2010) (104)
Interpreting patient/informant discrepancies of reported cognitive symptoms in MS (2005) (102)
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. (2011) (102)
Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. (2007) (101)
Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis (2009) (100)
The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging (2019) (100)
Cost-effectiveness of disease-modifying therapy for multiple sclerosis (2011) (99)
Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. (2010) (99)
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. (2005) (98)
Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis (2007) (96)
A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis (1998) (95)
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients (2010) (95)
Clinical features of neuromyelitis optica in children (2016) (95)
Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis (2007) (94)
Quercetin and interferon-β modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients (2008) (94)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (94)
Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. (2010) (93)
Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients (2013) (91)
Thalamic Involvement in Multiple Sclerosis: A Diffusion‐Weighted Magnetic Resonance Imaging Study (2003) (90)
Impact of diagnosis and early treatment on the course of multiple sclerosis. (2013) (90)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Characterizing cognitive function during relapse in multiple sclerosis (2014) (87)
Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study (2017) (86)
Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1 (1999) (85)
Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report (2011) (84)
Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. (2010) (84)
Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients (2016) (84)
Characteristics of Children and Adolescents With Multiple Sclerosis (2016) (83)
Venous angioplasty in patients with multiple sclerosis: results of a pilot study. (2012) (83)
MS disease activity in RESTORE (2014) (80)
Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. (2011) (79)
Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls (2016) (78)
Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis (2003) (78)
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study (2010) (77)
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician (2008) (76)
A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta (2005) (76)
Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study (2011) (72)
Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis (2003) (71)
Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. (2004) (71)
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS (2012) (71)
MRI features of pediatric multiple sclerosis (2007) (71)
Epstein–Barr virus is associated with grey matter atrophy in multiple sclerosis (2009) (70)
Gender-related differences in MS: a study of conventional and nonconventional MRI measures (2009) (69)
Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients (2003) (69)
Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network (2014) (68)
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study (2013) (68)
Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. (2018) (67)
Interferon β for Multiple Sclerosis. (2018) (66)
Validity of the California Verbal Learning Test–II in Multiple Sclerosis (2010) (66)
Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS (2011) (66)
Iron deposition in multiple sclerosis lesions measured by susceptibility‐weighted imaging filtered phase: A case control study (2012) (65)
Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis (2008) (64)
Fatigue and Depression in Children With Demyelinating Disorders (2013) (64)
Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. (2017) (63)
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. (2016) (63)
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients (2000) (63)
Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. (2010) (62)
Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. (2016) (61)
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients (2005) (61)
Distinct effects of obesity and puberty on risk and age at onset of pediatric MS (2016) (60)
Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency (2011) (59)
Multiple sclerosis gender issues: clinical practices of women neurologists (2004) (59)
Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis (2007) (59)
Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset (2015) (59)
Iron Deposition on SWI-Filtered Phase in the Subcortical Deep Gray Matter of Patients with Clinically Isolated Syndrome May Precede Structure-Specific Atrophy (2012) (59)
Construct validity and frequency of euphoria sclerotica in multiple sclerosis. (2004) (58)
A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. (2016) (58)
Genomic effects of IFN-beta in multiple sclerosis patients. (2003) (58)
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients (2017) (57)
Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5‐year longitudinal study (2018) (56)
Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) (2000) (56)
Increased tissue damage and lesion volumes in African Americans with multiple sclerosis (2010) (54)
Cyclophosphamide for multiple sclerosis. (2007) (54)
Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. (2009) (54)
Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis (2010) (53)
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis (2010) (53)
Dietary salt intake and time to relapse in paediatric multiple sclerosis (2016) (53)
Cine cerebrospinal fluid imaging in multiple sclerosis (2012) (51)
Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality (2018) (51)
Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study (2014) (50)
Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis (2020) (50)
Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity (2008) (49)
Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study (2019) (49)
Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers (2011) (48)
Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives (2011) (48)
Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset (2009) (48)
Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers (2013) (47)
Quantitative diffusion weighted imaging measures in patients with multiple sclerosis (2007) (47)
HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. (1998) (46)
Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-β (2009) (45)
Cortical atrophy and personality in multiple sclerosis. (2008) (45)
Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients (2007) (45)
Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis (2018) (45)
Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Patients with Multiple Sclerosis (2014) (44)
Intra- and Extraluminal Structural and Functional Venous Anomalies in Multiple Sclerosis, as Evidenced by 2 Noninvasive Imaging Techniques (2012) (44)
Speech and pause characteristics in multiple sclerosis: A preliminary study of speakers with high and low neuropsychological test performance (2013) (44)
Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study (2020) (44)
Prospective randomized trial of venous angioplasty in MS (PREMiSe) (2014) (43)
TREATMENT OF FULMINANT MULTIPLE SCLEROSIS WITH INTRAVENOUS CYCLOPHOSPHAMIDE (1997) (43)
Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions (2014) (43)
Differential effects of aging on motor and cognitive functioning in multiple sclerosis (2017) (42)
Benchmarks of meaningful impairment on the MSFC and BICAMS (2016) (41)
CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. (2010) (41)
Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies (2006) (41)
Negative work events and accommodations in employed multiple sclerosis patients (2014) (41)
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis (2013) (40)
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients[S] (2015) (40)
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) (40)
Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry (2019) (40)
Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow (2014) (40)
Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. (2013) (40)
Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS (2016) (39)
Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis (2011) (38)
Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US (2018) (38)
Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica (2008) (38)
Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients (2008) (37)
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain? (2016) (37)
The neurological disease ontology (2013) (37)
Interdependence of oxysterols with cholesterol profiles in multiple sclerosis (2017) (37)
Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes (2014) (36)
Mechanisms of interferon-beta effects on bone homeostasis. (2009) (36)
Gene–environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis (2009) (36)
Natalizumab in pediatric multiple sclerosis patients (2010) (36)
Cognitive Profiles of Aging in Multiple Sclerosis (2019) (35)
A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. (1998) (35)
MRI in the evaluation of pediatric multiple sclerosis (2016) (35)
Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. (2019) (35)
Interferon-β treatment for relapsing multiple sclerosis (2008) (34)
Visual-cognitive processing deficits in pediatric multiple sclerosis (2011) (34)
Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients (2006) (34)
Genetic risk factors for pediatric-onset multiple sclerosis (2018) (34)
Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis (2012) (33)
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later (2016) (33)
Disclosure of disease status among employed multiple sclerosis patients: Association with negative work events and accommodations (2015) (33)
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study (2013) (33)
Influence of Cognitive Function on Speech and Articulation Rate in Multiple Sclerosis (2012) (33)
The NEO-FFI in Multiple Sclerosis: Internal Consistency, Factorial Validity, and Correspondence Between Self and Informant Reports (2011) (33)
Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis (2013) (33)
Iron deposition and inflammation in multiple sclerosis. Which one comes first? (2011) (32)
Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients (2007) (31)
Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study (2019) (31)
Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition (2018) (31)
Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis (1999) (31)
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis (2013) (31)
Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis (2017) (31)
Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. (2011) (31)
Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. (2019) (31)
Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis (2011) (31)
An update on new and emerging therapies for relapsing-remitting multiple sclerosis. (2013) (31)
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study (2013) (31)
Two decades of glatiramer acetate: From initial discovery to the current development of generics (2017) (30)
Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective (2020) (30)
Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis (2013) (30)
Identifying employed multiple sclerosis patients at-risk for job loss: When do negative work events pose a threat? (2015) (30)
Patterns of dietary and herbal supplement use by multiple sclerosis patients (2012) (30)
Aging and Brain Atrophy in Multiple Sclerosis (2019) (30)
Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis (2018) (30)
Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis (2019) (29)
Cognition and physical disability in predicting health-related quality of life in multiple sclerosis. (2011) (29)
Randomized controlled trial of atorvastatin in clinically isolated syndrome (2012) (29)
Dicer and microRNA expression in multiple sclerosis and response to interferon therapy (2016) (29)
Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study[S] (2019) (28)
Comparison of intravascular ultrasound with conventional venography for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency. (2013) (28)
Regression-Based Norms Improve the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS) (2012) (28)
Recovery of cognitive function after relapse in multiple sclerosis (2020) (28)
Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain (2017) (28)
Improved relapse recovery in paediatric compared to adult multiple sclerosis. (2020) (28)
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials (1998) (28)
Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. (2018) (28)
Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium (2018) (27)
Regression-Based Pediatric Norms for the Brief Visuospatial Memory Test – Revised and the Symbol Digit Modalities Test (2011) (27)
Gray matter SWI-filtered phase and atrophy are linked to disability in MS. (2013) (27)
Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients[S] (2017) (27)
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis (2010) (27)
Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. (2011) (26)
Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus (2015) (26)
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis (2012) (26)
Improved cognitive performance and event-related potential changes following working memory training in patients with multiple sclerosis (2018) (26)
MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis (2009) (26)
Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. (2000) (26)
The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. (2011) (26)
Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals (2017) (26)
Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study (2017) (26)
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command (2009) (25)
Dynamics of immune cell trafficking in interferon-β treated multiple sclerosis patients (2003) (25)
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis (2016) (25)
Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS (2015) (25)
Hemostasis biomarkers in multiple sclerosis (2018) (25)
Cognitive impairment is associated with reduced bone mass in multiple sclerosis (2012) (25)
Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage (2018) (25)
Fingolimod for the treatment of relapsing multiple sclerosis (2011) (25)
Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis (2016) (24)
Arterial, venous and other vascular risk factors in multiple sclerosis (2012) (24)
Urban air quality and associations with pediatric multiple sclerosis (2018) (24)
Cerebellar mutism in pediatric acute disseminated encephalomyelitis. (2010) (24)
Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. (2006) (24)
Personality traits in women with multiple sclerosis: discrepancy in patient/partner report and disease course. (2009) (24)
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex) (2021) (24)
Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS (2017) (23)
Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis (2018) (23)
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis (2017) (23)
Treatment of multiple sclerosis in children and adolescents (2010) (23)
Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS (2019) (23)
Active Cognitive Reserve Influences the Regional Atrophy to Cognition Link in Multiple Sclerosis (2013) (23)
Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow‐up (2020) (22)
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE (2015) (22)
Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. (2019) (22)
Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine (2018) (22)
Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients (2020) (22)
Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients (2014) (22)
Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome (2014) (22)
Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study (2020) (22)
Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis (2011) (21)
Change in quality of life in patients with relapsing–remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon β-1a (2011) (21)
Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study (2014) (21)
Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study (2013) (21)
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis (2012) (21)
Dietary factors and pediatric multiple sclerosis: A case-control study (2018) (21)
The US Network of Pediatric Multiple Sclerosis Centers (2015) (21)
Dietary inflammatory index and risk of multiple sclerosis: Findings from a large population-based incident case-control study. (2020) (21)
Blood circulating microparticle species in relapsing–remitting and secondary progressive multiple sclerosis. A case–control, cross sectional study with conventional MRI and advanced iron content imaging outcomes (2015) (21)
Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. (2016) (21)
White matter tract network disruption explains reduced conscientiousness in multiple sclerosis (2018) (20)
Protective environmental factors for neuromyelitis optica (2014) (20)
Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study (2014) (20)
Tract‐based spatial statistics analysis of diffusion‐tensor imaging data in pediatric‐ and adult‐onset multiple sclerosis (2014) (20)
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years (2016) (19)
Impact of Nutritional Intake on Function in People with Mild-to-Moderate Multiple Sclerosis. (2019) (19)
Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study (2019) (19)
Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. (2019) (19)
Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk (2016) (19)
Vitamin D and Multiple Sclerosis (2012) (19)
Separate and Combined Influence of Cognitive Impairment and Dysarthria on Functional Communication in Multiple Sclerosis. (2018) (18)
Longitudinal personality change associated with cognitive decline in multiple sclerosis (2018) (18)
Interferon-beta treatment for relapsing multiple sclerosis. (2008) (18)
Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline (2019) (18)
Plasma pentosidine: a potential biomarker in the management of multiple sclerosis (2011) (18)
Heterogeneity in association of remote herpesvirus infections and pediatric MS (2018) (18)
Interferon inhibitory activity in patients with multiple sclerosis. (2006) (18)
An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis (2018) (18)
Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study (2019) (18)
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data (2021) (18)
Examining the contributions of environmental quality to pediatric multiple sclerosis. (2017) (17)
Vitamin D genes influence MS relapses in children (2020) (17)
Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. (2006) (17)
Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients☆ (2015) (17)
No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis (2012) (17)
Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI (2020) (17)
Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities (2012) (16)
Phase White Matter Signal Abnormalities in Patients with Clinically Isolated Syndrome and Other Neurologic Disorders (2014) (16)
Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis (2013) (16)
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis (2014) (16)
Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis (2016) (16)
The Management of Pediatric Multiple Sclerosis (2012) (15)
Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment? (2018) (15)
An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice—The MS‐MRIUS Study (2016) (15)
Combination Therapy for Multiple Sclerosis (2004) (15)
Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study (2014) (15)
Thalamic white matter in multiple sclerosis: A combined diffusion‐tensor imaging and quantitative susceptibility mapping study (2018) (15)
Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients (2011) (15)
Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis (2018) (15)
Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. (2019) (15)
Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimer's disease. (2018) (14)
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study (2012) (14)
Use of natalizumab in multiple sclerosis: current perspectives (2016) (14)
Functional Connectivity and Structural Disruption in the Default‐Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis (2020) (14)
High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus? (2019) (14)
Infectious exposure, antibiotic use, and multiple sclerosis: A population‐based incident case‐control study (2018) (14)
Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. (2007) (14)
Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross‐Sectional Structural MRI Study (2020) (14)
Functional imaging during covert auditory attention in multiple sclerosis (2004) (14)
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS (2015) (13)
Marijuana Use by Patients with Multiple Sclerosis. (2019) (13)
Stress-full life events and multiple sclerosis: A population-based incident case-control study. (2018) (13)
Gut microbiome is associated with multiple sclerosis activity in children (2021) (13)
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation (2016) (13)
Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls (2019) (13)
Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS (2012) (13)
An association between autoreactive antibodies and anti-interferon-β antibodies in multiple sclerosis (2007) (13)
Dalfampridine benefits ambulation but not cognition in multiple sclerosis (2020) (13)
What is New in the Treatment of Multiple Sclerosis? (2000) (13)
Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango (2014) (13)
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC) (2016) (13)
Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study (2018) (13)
Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson’s disease, mild cognitive impairment, Alzheimer’s disease, and elderly healthy controls (2020) (13)
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event (2011) (13)
Cognitive dysfunction in MS: bridging the gap between neurocognitive deficits, neuropsychological batteries and MRI (2008) (12)
Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study (2015) (12)
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review (2014) (12)
Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. (2011) (12)
Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures (2018) (12)
Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases (2021) (12)
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS‐MRIUS (2018) (12)
Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. (2020) (11)
Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both? (2021) (11)
Stable neuropsychiatric status in multiple sclerosis: a 3-year study (2016) (11)
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial (2015) (11)
MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. (2020) (11)
The role of dietary antioxidant index and index of nutritional quality in MS onset: finding from an Iranian population-based incident case–control study (2020) (11)
Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes (2013) (11)
MRI characteristics of familial and sporadic multiple sclerosis patients (2013) (11)
MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy (2014) (11)
The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing–Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study (2018) (11)
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. (2019) (11)
Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis (2020) (11)
Plasma levels of soluble NCAM in multiple sclerosis (2019) (11)
Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study (2019) (11)
Disease progression in pediatric multiple sclerosis: disparities between physical and neurocognitive outcomes (2011) (10)
Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis (2014) (10)
Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients (2020) (10)
Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis (2018) (10)
Parity Associated with Long-Term Disease Progression in Women with Multiple Sclerosis (P02.130) (2013) (10)
Prescribing Recommendations For Interferon-Beta In Multiple Sclerosis (1997) (10)
RESTORE Study: Effects of a 24-Week Natalizumab Treatment Interruption on Immune Parameters and Multiple Sclerosis Magnetic Resonance Imaging Disease Activity (P06.168) (2012) (10)
Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis (2020) (10)
Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis (2020) (9)
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses (2020) (9)
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology (2021) (9)
Sex‐Specific Differences in Life Span Brain Volumes in Multiple Sclerosis (2020) (9)
Staging and stratifying cognitive dysfunction in multiple sclerosis (2021) (9)
Multiple sclerosis: Extracranial venous angioplasty is ineffective to treat MS (2018) (9)
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis (2012) (9)
The nervous system's potential role in multiple sclerosis associated bone loss (2012) (9)
Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. (2018) (9)
miRNA contributions to pediatric‐onset multiple sclerosis inferred from GWAS (2019) (9)
Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study (2018) (9)
A new perspective on proxy report: Investigating implicit processes of understanding through patient–proxy congruence (2015) (9)
Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients. (2015) (8)
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis (2020) (8)
Cyclophosphamide for multiple sclerosis. (2002) (8)
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis (2020) (8)
Gut microbiome in early pediatric multiple sclerosis: a case-control study (P4.027) (2015) (8)
Long-term drug treatment in multiple sclerosis: safety success and concerns (2020) (8)
Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years (2020) (8)
Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: No (2013) (7)
Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis (2015) (7)
Gerstmann–Sträussler–Scheinker syndrome masquerading multiple sclerosis (2011) (7)
Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient (2021) (7)
Role of venoplasty for treatment of multiple sclerosis: value of open-label studies and surrogate treatment outcomes. (2012) (7)
Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis (2012) (7)
No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study (2018) (7)
Ontologies for the study of neurological disease (2012) (7)
Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. (2020) (7)
Several household chemical exposures are associated with pediatric‐onset multiple sclerosis (2018) (7)
Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. (2019) (7)
Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis (2020) (7)
Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1) (2009) (7)
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment (2021) (7)
A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis (2015) (7)
Is There Extra Cost of Institutional Care for MS Patients? (2013) (7)
Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population (2017) (7)
Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis (2017) (7)
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections (2022) (7)
A decline in cognitive function should lead to a change in disease-modifying therapy – Yes (2018) (7)
Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis (2021) (7)
Natalizumab Effects during a 6-Month Dose Interruption: Relationship of Pharmacokinetic (PK), Pharmacodynamic (PD), and MRI Measurements (S41.003) (2013) (7)
Pediatric Multiple Sclerosis Severity Score in a large US cohort (2020) (7)
Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold? (2014) (6)
Lipid pro fi les are associated with lesion formation over 24 months in interferon-β treated patients following the fi rst demyelinating event (2013) (6)
Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke? (2018) (6)
Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. (2012) (6)
Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy (2020) (6)
Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena? (2019) (6)
Vitamin D and multiple sclerosis: can vitamin D prevent disease progression? (2011) (6)
Serum neurofilament light chain and optical coherence tomography measures in MS (2020) (6)
Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives (2019) (6)
FP39-WE-02 A 15-year follow-up study to identify early predictors of long-term response to intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis (2009) (6)
No Regional Gray Matter Atrophy Differences between Pediatric‐ and Adult‐Onset Relapsing‐Remitting Multiple Sclerosis (2014) (6)
Association Between Time Spent Outdoors and Risk of Multiple Sclerosis (2021) (6)
Late onset multiple sclerosis is associated with more severe ventricle expansion. (2020) (6)
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial (2021) (6)
Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study (2016) (5)
Increased body mass index is causally associated with pediatric MS onset: A Mendelian randomization study (P1.375) (2016) (5)
Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study. (2022) (5)
Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis. (2017) (5)
Newer Versus Older Treatments for Relapsing-Remitting Multiple Sclerosis (1996) (5)
Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study (2018) (5)
Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis (2019) (5)
Diagnosis of depression in multiple sclerosis is predicted by frontal–parietal white matter tract disruption (2020) (5)
First Genome-Wide Analysis in Pediatric Multiple Sclerosis (MS) Confirms a Role for Adult MS Risk Variants and Reveals New Candidates (S29.001) (2016) (5)
Transitions between SNF and home-based care in patients with multiple sclerosis. (2014) (5)
Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic (2022) (5)
Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. (2008) (5)
High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis (2020) (4)
Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis (2020) (4)
Treatment of pain, paresthesias and paroxysmal disorders in multiple sclerosis (2007) (4)
Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Multiple Sclerosis Patients (2013) (4)
Decrease in secondary neck vessels in multiple sclerosis: A 5-year longitudinal magnetic resonance angiography study. (2019) (4)
A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis (2019) (4)
Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis (2019) (4)
Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report. (2016) (4)
Emerging therapies for multiple sclerosis (1996) (4)
No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years (2019) (4)
Fatigue and Depression Are Seen More Frequently in Children with Pediatric Acquired Demyelinating Disorders (ADS) Than Healthy Controls (HC) (P04.107) (2012) (4)
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. (2021) (4)
New MRI criteria in the diagnosis of multiple sclerosis (2007) (4)
Medical History and Multiple Sclerosis: A Population-Based Incident Case-Control Study (2018) (4)
Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes (2021) (4)
Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients (2013) (3)
A case-control study of dietary salt intake and risk of pediatric multiple sclerosis (MS) (S38.003) (2015) (3)
Parity Associated with Long-Term Disease Progression in Women with Multiple (2014) (3)
Longitudinal Magnetic Resonance Imaging of Cerebral Microbleeds in Multiple Sclerosis Patients (2020) (3)
Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution (2022) (3)
Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis (2019) (3)
An Ontological Representation and Analysis of Patient-reported and Clinical Outcomes for Multiple Sclerosis (2014) (3)
Unusual long-standing Gd-DTPA enhancement in a chronic progressive myelopathy. (1995) (3)
Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis (2017) (3)
Iron Deposition on SWI Filtered Phase in the Subcortical Deep Gray Matter of Clinically Isolated Syndrome Patients May Precede Structure-Specific Atrophy (P03.032) (2012) (3)
Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study (2012) (3)
Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. (2020) (3)
Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis (2020) (3)
Functional network dynamics and decreased conscientiousness in multiple sclerosis (2021) (3)
Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI (2021) (3)
Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis: A Longitudinal, Magnetic Resonance Imaging, Blinded Pilot Study (2010) (3)
Regarding CCSVI and MS: a never-ending story or a new chapter? (2012) (3)
Comment on “no evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset” (2011) (3)
Multicenter Retrospective Study Of Extended Dosing Of Natalizumab In Multiple Sclerosis: A Strategy For Mitigating Risk Of Progressive Multifocal Leukoencephalopathy While Maintaining Efficacy? (P2.251) (2014) (2)
Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. (2021) (2)
Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis (2021) (2)
Impact of Cognitive Impairment and Dysarthria on Spoken Language in Multiple Sclerosis (2020) (2)
Vitamin D: Role in Pathogenesis of Multiple Sclerosis (2016) (2)
Moving on to second-line therapies in pediatric MS (2009) (2)
Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis (2021) (2)
Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study (2021) (2)
Recurrent Pseudotumoral Demyelinating Disease in an Adolescent Patient (2014) (2)
Is Multiple Sclerosis Associated With a Lower Intraocular Pressure? (2017) (2)
Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. (2020) (2)
Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis (2008) (2)
Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. (2020) (2)
Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis (2021) (2)
Considering patient age when treating multiple sclerosis across the adult lifespan (2021) (2)
Assessing no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis receiving fingolimod: results from a longitudinal, multicenter, real-world study (P4.388) (2017) (2)
Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions. (2021) (2)
Treatment of natalizumab-induced PML with cidofovir or CMX001 (brincidofovir) and mirtazapine (P5.380) (2018) (2)
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. (2014) (2)
Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis (2022) (2)
Quantitative venous vasculature assessment on susceptibility-weighted imaging reflects presence of s (2010) (1)
Comorbidities breakout group discussion (2014) (1)
Safety and Efficacy of Extended Dose Natalizumab in Multiple Sclerosis: An Ongoing Multicenter Study. (P3.267) (2015) (1)
Peripheral nervous system electrodiagnostic abnormalities in predominantly Hispanic Multiple Sclerosis patients. (2021) (1)
Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis (2022) (1)
Multiple Sclerosis Patients with Allergies Demonstrate Better Physical Outcomes but Worse Psychological Symptoms. (P6.172) (2014) (1)
Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient (2021) (1)
Iron Deposition in Multiple Sclerosis Lesions Measured by Susceptibility-Weighted Imaging Filtered Phase. A Case Control Study (P03.042) (2012) (1)
Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis (2022) (1)
Quantitative Susceptibility Mapping Study of Deep Gray Matter Iron at 3T in Large Cohort of Multiple Sclerosis Patients (P4.162) (2016) (1)
Sensory Abnormalities in MS (2004) (1)
Effect of Obesity and Puberty on Risk and Age at Onset of Pediatric MS (S29.003) (2016) (1)
Personalized Management of Multiple Sclerosis (2013) (1)
Three-Day Dietary Manipulation in Multiple Sclerosis: Exercise and Fatigue Outcomes. (2021) (1)
Natalizumab improves health-related quality of life in patients with relapsing multiple sclerosis (2006) (1)
Neurologic complications of immunosuppressive and anti-inflammatory therapy for rheumatic diseases. (1996) (1)
Multiple sclerosis: predicting risk and delaying progression (2010) (1)
Dietary Factors and Risk of Pediatric Multiple Sclerosis (S29.006) (2016) (1)
Impact of fingolimod on MRI brain volume measures in routine clinical practice: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients (P5.350) (2017) (1)
Whole Brain and Lateral Ventricular Volume Changes are associated with Development of Disability Progression in Multiple Sclerosis: Results from a Large-Scale Clinical Routine 5-Year Observational Study (P3.356) (2018) (1)
Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis (P3.062) (2016) (1)
Monitoring Disease Progression in Aging Population with Multiple Sclerosis (P5.203) (2015) (1)
Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-world study is associated with disability progression (2022) (1)
The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. (2021) (1)
The neurological disease ontology (2013) (1)
Devic's disease: Diagnostic and therapeutic challenge (1997) (1)
Maternal Illness in Pregnancy and Perinatal Exposure to Pesticides Are Associated with Risk for Pediatric Onset MS (S29.005) (2016) (1)
Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis (2021) (1)
Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients (2022) (1)
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly (2015) (1)
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study (P05.134) (2013) (1)
Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon beta-1a users. (2023) (1)
A Paleolithic Diet-Based Intervention Decreases Multiple Sclerosis Fatigue via Lipid Profile Changes (P2.358) (2018) (1)
Longitudinal Evaluation of Cognitive Functioning in Pediatric Multiple Sclerosis (MS): Report from the U.S. Pediatric Multiple Sclerosis Network (S33.004) (2014) (1)
Limb Ataxia Originating from Peri-Central Sulcus Demyelinating Lesion in Multiple Sclerosis Patients (P06.176) (2012) (1)
Preliminary Support of a Behavioral Intervention for Trait Conscientiousness in Multiple Sclerosis. (2021) (1)
A Pediatric Case of NMOSD with Positive Seroconversion of AQP4-ab after 5 Years and Subsequent Diagnosis of SLE (2017) (1)
The incidence and clinical significance of antibodies to natalizumab over 2 years of treatment in patients with multiple sclerosis (2006) (1)
Repeated forms, testing intervals, and SDMT performance in a large multiple sclerosis dataset. (2022) (1)
Effects of a 24-Week Natalizumab Treatment Interruption on Quality of Life, Fatigue, and Cognition: Results from the RESTORE Study (P06.171) (2012) (1)
Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis. (2022) (1)
Evidence-based guideline : Complementary and alternative medicine in multiple sclerosis Report of the Guideline Development Subcommittee of the American Academy of Neurology (2014) (1)
Humoral Response to Epstein-Barr virus is Associated with Cortical Pathology in Patients with Multiple Sclerosis (P5.236) (2015) (1)
Pain in patients with multiple sclerosis: Effects of natalizumab (2008) (1)
Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. (2018) (1)
Evaluation of Shorter Infusion Times with Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (2019) (0)
Multiple Sclerosis and Associated Comorbidities (2018) (0)
Feasibility of brain atrophy measurement in clinical routine: Results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients (S12.004) (2017) (0)
Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study (2023) (0)
Multiple Sclerosis and Cancer (P1.119) (2015) (0)
Impaired Cognition without Behavioral Problems in Pediatric Clinically Isolated Syndrome (CIS) (P02.113) (2013) (0)
Monthly screening for neuropsychological impairment in multiple sclerosis (2007) (0)
The Expanded Timed Up-and-Go (ETUG) is significantly and strongly correlated with EDSS in multiple sclerosis patients (P1.370) (2017) (0)
Treatment Considerations in Female MS Patients of Reproductive Age (2017) (0)
Disappearing Brainstem MRI Lesions in Multiple Sclerosis (P3.353) (2018) (0)
Persistent spinal cord enhancement in longitudinal extensive transverse myelitis associated with α-1-antitrypisn deficiency: a case report (2022) (0)
Increased Prevalence of Contrast Enhancing Lesions in Multiple Sclerosis Migraine Patients (P6.117) (2015) (0)
Decrease in size of secondary neck vessels and cerebral aqueduct enlargement in multiple sclerosis: a 5-year longitudinal MRI study (2019) (0)
Comparative effectiveness of natalizumab and fingolimod and injectable therapies in patients with pediatric multiple sclerosis: A registry-based retrospective cohort study (2022) (0)
Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis (2022) (0)
Humoral Responses to Systemic and Organ Specific Auto-Antigens in Multiple Sclerosis (P4.010) (2015) (0)
Real-world effectiveness of switching treatment after initial platform injectable disease-modifying therapies in pediatric multiple sclerosis in the US (P14-3.008) (2023) (0)
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients patient-oriented and epidemiological research (2020) (0)
Iron Deposition in the Subcortical Deep-Gray Matter of Pediatric Multiple Sclerosis Patients (S50.006) (2012) (0)
Preservation of Functional Connectivity Moderates the Impact of White Matter Tract Disruption on Cognition in Multiple Sclerosis (S44.008) (2018) (0)
Multiple Sclerosis: Experience with Large Clinical Trials (2001) (0)
Disease Modifying Therapies : Prevention of Relapses (2012) (0)
Regarding CCSVI: is blinding the key? (2012) (0)
Pregnancy Decision-making for Women with Multiple Sclerosis (P4.159) (2014) (0)
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis (2022) (0)
Thalamic tract integrity changes are associated with cognition and disinhibition in multiple sclerosis (2014) (0)
Successful Treatment of Natalizumab Induced PML with CMX001 and the Side Effects Associated with Its Use (P07.060) (2012) (0)
Susceptibility networks reveal independent patterns of brain iron abnormalities in multiple sclerosis (2022) (0)
Characteristics and Predictors of Disease Course in Children Initially Presenting with Acute Disseminated Encephalomyelitis (ADEM) (2021) (0)
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. (2022) (0)
Immunomodulatory therapies are associated with comorbid autoimmune diseases in MS patients (2013) (0)
PND36 POTENTIAL BARRIERS TO HOME CARE USE AMONG PATIENTS WITH MULTIPLE SCLEROSIS (2010) (0)
The relationship between disease severity and health-related quality of life in patients with relapsing multiple sclerosis (2006) (0)
Obtaining Patient and Family Views in Pediatric MS Research Needs, Outcomes and Methods: Study Design (P2.129) (2016) (0)
Prolonged Timed Up and Go Is Associated with Falls and Patient Self-Reported Mobility Limitations (P2.137) (2016) (0)
Rare and low-frequency coding genetic variants contribute to pediatric-onset multiple sclerosis (2023) (0)
Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis. (2023) (0)
Subcortical Deep Gray Matter SWI-Filtered Phase and Atrophy Are Associated with Disability in MS (S21.005) (2012) (0)
Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives (2022) (0)
Cognition and disinhibition in multiple sclerosis : impact of MRI changes within thalamic tracts Submitted (2016) (0)
High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: Afatigue-metabolism nexus? (2019) (0)
Interferon beta-1a Treatment Inhibits Th1- and Th17-Cell Responses in Patients with Relapsing-Remitting Multiple Sclerosis (P05.144) (2013) (0)
Multiple Sclerosis Subtypes: How the Natural History of Multiple Sclerosis Was Challenged due to Treatment (2016) (0)
Diffusion tensor imaging alterations of subcortical deep grey matter in clinically isolated syndrome patients: a case control study (2013) (0)
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC). (2022) (0)
Reversibility of Natalizumab Effects on Peripheral Immune Cell Dynamics in Patients with Multiple Sclerosis (2017) (0)
Dentate nucleus T1 hyperintensity in early relapsing-remitting multiple sclerosis patients is associated with cumulative gadopentetate dimeglumine (Gd-DTPA) administration (S6.007) (2018) (0)
Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis (2022) (0)
Corrigendum to “Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis: A case–control diffusion imaging study” [Pathophysiology 18 (2011) 61–68] (2011) (0)
Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis (P12-3.001) (2023) (0)
Leptomeningeal Contrast Enhancement is Associated with Development of Gray Matter Atrophy Over 5 Years in Multiple Sclerosis (S41.006) (2016) (0)
Associations Between Changes in Ferritin Levels and Susceptibility-Weighted Imaging Filtered Phase in Patients with Relapsing-Remitting Multiple Sclerosis over Six Months Therapy with Interferon Beta-1a (P6.115) (2014) (0)
ELISPOT analysis of proteolipid protein (PLP) cytokine responses in multiple sclerosis (MS) (1998) (0)
Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis (2006) (0)
Smoking in Multiple Sclerosis Patients is Negatively Associated with Patient Perceived Psychosocial Factors (P6.177) (2014) (0)
Recurrent isolated optic neuritis in the pediatric population (2011) (0)
PP2-076 Immmunomodulation by quercetin and interferon-β in multiple sclerosis patientsImmmunomodulation by quercetin and interferon-β in multiple sclerosis patients (2009) (0)
Changes in Immunological Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Interferon Beta-1a (P4.132) (2014) (0)
The Effect Of Cardiovascular Risk Factors On Lesion Burden And Brain Atrophy In Multiple Sclerosis (S54.006) (2014) (0)
Other therapeutics in the pipeline & future directions (2011) (0)
EXERCISE IMPROVES SIT-TO-STAND FUNCTION IN PEOPLE WITH MULTIPLE SCLEROSIS (2012) (0)
Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis: A Case-Control Cross-sectional and Longitudinal Analysis (2022) (0)
Demographic and Clinical Characteristics of 490 Children and Adolescents with Multiple Sclerosis (MS): US Network of Pediatric MS Centers’ Experience (S29.004) (2016) (0)
Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient (2021) (0)
Multiple sclerosis in 2019: predicting progression (2020) (0)
A lexical access deficit in Clinical Isolated Syndrome : correlation with brain MRI parameters (0)
Menarche and Relapses in Girls with Pediatric Multiple Sclerosis (1270) (2020) (0)
Machine-learning-based prediction of disability progression in multiple sclerosis: an observational, international, multi-center study (2022) (0)
Natalizumab Discontinuation Study: taper protocol may prevent disease reactivation (P3.287) (2015) (0)
MOG and Aquaporin-4 Antibody Frequency, Clinical and MRI Characteristics, and Disease Course Among Children Diagnosed with MS and Controls (2021) (0)
Predicting MS After an Initial Demyelinating Event in Children (2009) (0)
Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis (625) (2020) (0)
Characteristics of Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Switching First-Line Therapies for Different Reasons (P01.212) (2013) (0)
Neurology Development Subcommittee of the American Academy of alternative medicine in multiple sclerosis : Report of the Guideline Summary of evidence-based guideline : Complementary and (0)
A composite outcome measure to monitor clinical response to M.S. treatment protocols (1995) (0)
Longitudinal Cognitive Screening Findings in Pediatric MS vs. Pediatric Controls and Adult MS in a Multi-center Cohort (S31.008) (2023) (0)
Retinal blood vessel analysis using optical coherence tomography in multiple sclerosis (2022) (0)
Short communication Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients (2007) (0)
Therapy effect on AI-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study. (2023) (0)
PASAT with the Symbol Digit Modalities Test Psychometrics and normative data for the Multiple Sclerosis Functional Composite : replacing the (2010) (0)
Elispot analysis of PLP responses in MS (1998) (0)
ACTRIMS Forum 2021 – Invited Program (2021) (0)
Clinical and Demographic Features of Children with NMO: Report from the U.S. Network of Pediatric MS Centers of Excellence (S63.003) (2014) (0)
Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives (2022) (0)
Neuroinflammatory Disease in Association with Morphea (Localized Scleroderma) (2017) (0)
Does First Year MRI and Clinical Activity Correlate with Long Term Clinical Response to Glatiramer Acetate in Multiple Sclerosis Patients? (P01.194) (2013) (0)
The Causal Effect of Serum Vitamin D Levels on Pediatric Multiple Sclerosis: A Mendelian Randomization Study (S29.007) (2016) (0)
Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a (P3.146) (2014) (0)
Effect of switching from daily injections of 20mg glatiramer acetate to 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis over 33 months (P2.398) (2017) (0)
Functional alteration due to structural damage is network dependent: insight from multiple sclerosis. (2022) (0)
Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder (2022) (0)
Correlations between Immunological Biomarkers and Conventional and Advanced MRI Measures Following Interferon Beta-1a Treatment for Relapsing-Remitting Multiple Sclerosis (P3.147) (2014) (0)
Natalizumab treatment interruption: RESTORE study baseline data (2011) (0)
Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis (2023) (0)
Environmental Risk Factors Associated with Pediatric Neuromyelitis Optica (P02.157) (2013) (0)
Viral and Genetic Risk Factors for Pediatric Neuromyelitis Optica (P02.114) (2013) (0)
Multiple Sclerosis and Related Disorders (2016) (0)
Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry (2018) (0)
Patterns of Use and Safety of Newer Disease-modifying therapies in Pediatric Multiple Sclerosis in the US (S51.004) (2018) (0)
Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study (2023) (0)
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic (2022) (0)
EBV, CMV, and HSV IgG Titers Are Not Predictive of Subsequent Relapse Risk in Pediatric Multiple Sclerosis (P02.096) (2012) (0)
Evolution of Brain Iron Levels in Multiple Sclerosis: A 2-Year Longitudinal Quantitative Susceptibility Mapping Study at 3T (P4.163) (2016) (0)
Quality of life perceptions correlate with longitudinal clinical relapse reduction metrics in patients treated with subcutaneous interferon beta-1a given three times a week. (P1.113) (2015) (0)
SDGM iron and atrophy are related to disability in MS 526 The most frequent approach for visualizing iron deposition in vivo (2012) (0)
Safety and Efficacy of Ocrelizumab in Multiple Sclerosis Patients with increased disability (P6.353) (2018) (0)
Nucleus-specific abnormal thalamic resting state functional connectivity in multiple sclerosis (2016) (0)
Leptomeningeal inflammation is related to cortical thinning in relapsing-remitting multiple sclerosis (S6.008) (2018) (0)
A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis (2022) (0)
Silent findings: Examination of asymptomatic demyelination in a pediatric US cohort. (2023) (0)
Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis (2023) (0)
Fitts’ Tapping Task as a New Test for Cognition and Manual Dexterity in Multiple Sclerosis: Validation Study (2022) (0)
Phytosterols (PS) as immunomodulators of Multiple Sclerosis (MS) (2010) (0)
Feasibility of Brain AtrophyMeasurement in Clinical Routine without Prior Standardization of theMRI Protocol : Results fromMS-MRIUS , a Longitudinal Observational , Multicenter Real-World Outcome Study in Patients with Relapsing-RemittingMS (2017) (0)
Hypertension and heart disease are independently associated with development of brain atrophy in multiple sclerosis patients. A 5-year longitudinal study (P2.345) (2018) (0)
Baseline Characteristics of the CHORDS Study Population: A Phase III Trial to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With RRMS Who Had Disease Activity With Prior Disease-Modifying Therapies (P6.370) (2018) (0)
Evaluation of neuroinflammation in experimental autoimmune encephalomyelitis (EAE) mice with animal PET and MRI (2009) (0)
Other therapeutics in the pipeline and future directions (2012) (0)
Disability accrual in primary and secondary progressive multiple sclerosis (2023) (0)
Gene–environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures (2023) (0)
Allergies in Pediatric Multiple Sclerosis: A Case-Control Study (P1.380) (2016) (0)
Fat, fiber, and pediatric MS (S38.002) (2015) (0)
Prognostic immunological markers in patients with relapsing-remitting multiple sclerosis: a prospective magnetization transfer brain imaging study (P3117) (2013) (0)
Nursing Home MS Residents Experience Less Stress and Pessimism Compared to Home-Based Non-Ambulatory MS Patients. (P4.153) (2014) (0)
Development Of An Innovative Observational Study To Assess Multiple Sclerosis Disease Progression In Real World Clinical Practice (2016) (0)
Additive interaction between dietary inflammatory index and some key risk factors of multiple sclerosis: a population-based incident case-control study. (2022) (0)
Cerebellar Mutism in Pediatric Acute Disseminated Encephalomyelitis. Authors' reply (2010) (0)
2009 ACTRIMS ABSTRACTS: Oral Presentations (2009) (0)
Lawrence D. Jacobs, MD (1938–2001) (2002) (0)
Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) (P05.127) (2012) (0)
Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy (2020) (0)
Iron Content in Benign and Non-Benign Patients with Relapsing-Remitting Multiple Sclerosis (P06.108) (2013) (0)
Role of Nutritional Factors in Multiple Sclerosis (2014) (0)
A new look at cognitive functioning in pediatric MS (2022) (0)
Multiple Sclerosis Therapeutics: Management of pediatric multiple sclerosis (2011) (0)
A possible influence of fatigue in the risk of work accidents in a sample of MS patients (2013) (0)
MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls (2022) (0)
Subtle Lesion Appearance on MRI May Precede Development of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients Treated with Natalizumab (P07.059) (2012) (0)

This paper list is powered by the following services:

Other Resources About Bianca Weinstock-Guttman

en.wikipedia.org

What Schools Are Affiliated With Bianca Weinstock-Guttman?

Bianca Weinstock-Guttman is affiliated with the following schools:

Bianca Weinstock-Guttman's Academic­Influence.com Rankings

Bianca Weinstock-Guttman's Degrees

Why Is Bianca Weinstock-Guttman Influential?

Bianca Weinstock-Guttman's Published Works

Published Works

Other Resources About Bianca Weinstock-Guttman

What Schools Are Affiliated With Bianca Weinstock-Guttman?

Bianca Weinstock-Guttman's AcademicInfluence.com Rankings